4.74
price down icon1.04%   -0.05
after-market アフターアワーズ: 4.74
loading
前日終値:
$4.79
開ける:
$4.79
24時間の取引高:
401.04K
Relative Volume:
0.88
時価総額:
$279.35M
収益:
$192.64M
当期純損益:
$2.51M
株価収益率:
90.46
EPS:
0.0524
ネットキャッシュフロー:
$12.42M
1週間 パフォーマンス:
-0.84%
1か月 パフォーマンス:
+2.82%
6か月 パフォーマンス:
+7.73%
1年 パフォーマンス:
-22.93%
1日の値動き範囲:
Value
$4.71
$4.835
1週間の範囲:
Value
$4.60
$4.95
52週間の値動き範囲:
Value
$3.8092
$6.26

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Name
名前
Vanda Pharmaceuticals Inc
Name
セクター
Healthcare (1164)
Name
電話
202-734-3400
Name
住所
2200 PENNSYLVANIA AVE NW, WASHINGTON
Name
職員
368
Name
Twitter
Name
次回の収益日
2025-05-02
Name
最新のSEC提出書
Name
VNDA's Discussions on Twitter

VNDA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
VNDA
Vanda Pharmaceuticals Inc
4.74 282.30M 192.64M 2.51M 12.42M 0.0524
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-10-31 開始されました H.C. Wainwright Buy
2024-07-11 開始されました Cantor Fitzgerald Overweight
2022-02-25 ダウングレード Jefferies Buy → Hold
2021-05-12 開始されました BofA Securities Buy
2021-01-14 ダウングレード Citigroup Buy → Neutral
2020-10-29 アップグレード Citigroup Neutral → Buy
2020-06-09 ダウングレード Citigroup Buy → Neutral
2020-03-16 ダウングレード Oppenheimer Perform → Underperform
2020-03-12 アップグレード Citigroup Neutral → Buy
2019-11-07 ダウングレード Citigroup Buy → Neutral
2019-08-01 アップグレード Citigroup Neutral → Buy
2019-07-25 ダウングレード Stifel Buy → Hold
2018-12-11 ダウングレード Oppenheimer Outperform → Perform
2018-12-04 アップグレード Cantor Fitzgerald Neutral → Overweight
2018-12-04 繰り返されました Jefferies Buy
2018-11-08 再開されました Jefferies Buy
2018-09-21 再開されました Oppenheimer Outperform
2018-05-23 開始されました Citigroup Buy
2018-01-19 開始されました Seaport Global Securities Buy
2017-09-14 繰り返されました Piper Jaffray Overweight
2017-06-27 再開されました Piper Jaffray Overweight
2017-05-26 開始されました H.C. Wainwright Buy
2017-04-12 開始されました Oppenheimer Outperform
2016-11-09 開始されました Aegis Capital Buy
2016-10-06 再開されました Jefferies Buy
すべてを表示

Vanda Pharmaceuticals Inc (VNDA) 最新ニュース

pulisher
03:34 AM

How does Vanda Pharmaceuticals Inc. generate profit in a changing economyBuild a diversified portfolio for stability - jammulinksnews.com

03:34 AM
pulisher
03:31 AM

Should I hold or sell Vanda Pharmaceuticals Inc. stock in 2025Free Stock Market Query - jammulinksnews.com

03:31 AM
pulisher
12:59 PM

Is Vanda Pharmaceuticals Inc. a growth stock or a value stockExceptional trading performance - jammulinksnews.com

12:59 PM
pulisher
Jul 25, 2025

Is Vanda Pharmaceuticals Inc. a good long term investmentRapid wealth accumulation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

When is the best time to buy Vanda Pharmaceuticals Inc. stockPowerful profit generation - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 - Barchart.com

Jul 24, 2025
pulisher
Jul 23, 2025

Vanda Pharmaceuticals Inc. Stock Analysis and ForecastSkyrocketing investment returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Vanda Pharmaceuticals Inc. stockAccelerated capital growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Vanda Pharmaceuticals Inc. stock priceMassive profits - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

Why Vanda Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Growth Low Risk Picks - beatles.ru

Jul 19, 2025
pulisher
Jul 17, 2025

Vanda Pharmaceuticals’ Study on Trichostatin A: A Potential Game-Changer in Hematologic Malignancies - TipRanks

Jul 17, 2025
pulisher
Jul 09, 2025

US FDA Will Not Pull Teva And MSN Hetlioz ANDAs, Rejects Vanda Citizen Petitions - insights.citeline.com

Jul 09, 2025
pulisher
Jun 30, 2025

Vanda Pharmaceuticals Inc.(NasdaqGM: VNDA) added to Russell 2000 Defensive Index - MarketScreener

Jun 30, 2025
pulisher
Jun 17, 2025

Insider Sell: Stephen Mitchell Sells 7,000 Shares of Vanda Pharm - GuruFocus

Jun 17, 2025
pulisher
Jun 13, 2025

DC Circ. Urged To Reject Approval For Braille-Free Drug Label - Law360

Jun 13, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S - StreetInsider

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed In A Trial Evaluating VCA-894A In Charcot-Marie-Tooth Disease Type 2S - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial E - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals (VNDA) Initiates First Human Trial for Ant - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda's Breakthrough: First-Ever Personalized Treatment Trial Launches for Ultra-Rare CMT2S Disease - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S | VNDA Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 09, 2025

Director Honore Tage was granted 59,225 shares, increasing direct ownership by 92% to 123,469 units (SEC Form 4) - Quantisnow

Jun 09, 2025
pulisher
Jun 05, 2025

Vanda Approves Key Proposals at Annual Meeting - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

SEC Form S-8 filed by Vanda Pharmaceuticals Inc. - Quantisnow

Jun 05, 2025
pulisher
Jun 05, 2025

CLASS ACTION UPDATE for SPB, VNDA and ARA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 03, 2025

Class Action Reminder Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 03, 2025

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm - ACCESS Newswire

Jun 03, 2025
pulisher
May 29, 2025

Judge Favors Vanda But Seeks Deal Over Drug Approval - Law360

May 29, 2025
pulisher
May 27, 2025

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting | VNDA Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting - PR Newswire

May 27, 2025
pulisher
May 27, 2025

SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc. - Quantisnow

May 27, 2025
pulisher
May 27, 2025

Clinical Data: Vanda Unveils Key Bioequivalence Study Results for Next-Gen Psychiatric Drug at Major Conference - Stock Titan

May 27, 2025
pulisher
May 22, 2025

Justices Urged To Undo Denial Of Fast Track For Gastro Drug - Law360

May 22, 2025

Vanda Pharmaceuticals Inc (VNDA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
大文字化:     |  ボリューム (24 時間):